Afuco™ Anti-Human IL13 ADCC Recombinant Antibody (RPC4046), ADCC Enhanced (CAT#: AFC-379CL)

Figure 1 At week 16, mean reductions from baseline in esophageal eosinophil count were 4.42 ± 59.94, 94.76 ± 67.27, and 99.90 ± 79.53 eos/hpf in the placebo, 180 mg RPC4046, and 360 mg RPC4046 groups, respectively.

Mean changes between either RPC4046 dose and placebo were statistically significant at week 16 (P < .0001 for both comparisons; mean counts). Peak esophageal eosinophil counts were significantly reduced, with 50% of patients treated with 180 mg and 360 mg having <15 peak eos/hpf compared with 0% placebo (P < .0001 for both comparisons), and 25% of patients in the 180 mg RPC4046 group and 20% in the 360 mg RPC4046 group having <6 peak eos/hpf after treatment (P = .0027 and P = .0079, respectively).

Hirano, I., Collins, M. H., Assouline-Dayan, Y., Evans, L., Gupta, S., Schoepfer, A. M., ... & Tompkins, C. A. (2019). RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Gastroenterology, 156(3), 592-603.

Figure 2 For overall EoE patient group, mean patient’s global assessment of disease severity was significantly reduced at week 16 for the 360-mg RPC4046 group compared with placebo.

Mean reductions in the patient's global assessment of disease severity score of 2.01 ± 1.68 and 2.8 ± 2.71 were significant at week 16 with the 360-mg dose (n = 27, P = .0107) but not with the 180-mg dose (n = 30, P = .1035) (Figure A). Mean reductions in the clinician's global assessment of disease severity score of 3.6 ± 2.71 and 2.9 ± 2.70 were significant at week 16 with the 180-mg (n = 27, P = .0094) and 360-mg doses (n = 30, P = .0352) (Figure B). Categorical analysis of patient's global impression of change in EoE symptoms at week 16 did not show significant improvements in either RPC4046 group (180 mg: n = 31, P = .4094; 360 mg: n = 34, P = .0143) (Figure C).

Hirano, I., Collins, M. H., Assouline-Dayan, Y., Evans, L., Gupta, S., Schoepfer, A. M., ... & Tompkins, C. A. (2019). RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Gastroenterology, 156(3), 592-603.